FOLD: second_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/81d5fadb-ecfb-4ef5-955e-130f160ced60/","filing_uuid":"81d5fadb-ecfb-4ef5-955e-130f160ced60","filing_type":"2T","filing_type_display":"2nd Quarter - Termination","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/81d5fadb-ecfb-4ef5-955e-130f160ced60/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Allegra M. Han","dt_posted":"2026-07-16T15:36:04-04:00","termination_date":"2026-04-15","registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"700 13th Street NW, 2nd Floor","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":313715,"url":"https://lda.gov/api/v1/registrants/313715/","house_registrant_id":39384,"name":"CAPITOL COUNSEL LLC","description":"Government affairs.","address_1":"700 13th Street NW, 2nd Floor","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"TRACEY A. GRAY","contact_telephone":"+1 202-861-3200","dt_updated":"2026-07-31T14:55:49.985763-04:00"},"client":{"id":71466,"url":"https://lda.gov/api/v1/clients/71466/","client_id":71466,"name":"AMICUS THERAPEUTICS, INC.","general_description":"Biopharmaceutical company.","client_government_entity":null,"client_self_select":false,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-02-05"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Legislative and regulatory issues affecting SMID rare disease biotech companies. FDA approvals of rare diseases.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143156,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152462,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"STONE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153079,"prefix":"mr","prefix_display":"MR.","first_name":"CHARLES","nickname":null,"middle_name":"PATRICK","last_name":"MICHAELS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Legislative and regulatory issues affecting SMID rare disease biotech companies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143156,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152462,"prefix":null,"prefix_display":null,"first_name":"KAREN","nickname":null,"middle_name":null,"last_name":"STONE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153079,"prefix":"mr","prefix_display":"MR.","first_name":"CHARLES","nickname":null,"middle_name":"PATRICK","last_name":"MICHAELS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}